{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:14:20Z","timestamp":1781111660347,"version":"3.54.1"},"reference-count":10,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.3201\/eid3103.241473","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:56:56Z","timestamp":1740178616000},"source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment"],"prefix":"10.3201","volume":"31","author":[{"given":"Valentina","family":"Gerussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Bachir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Poignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Rached","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doroth\u00e9e","family":"Vallois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Veziris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Guglielmetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3103.241473-202502181628-R1","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment, 2022 update. Geneva: The Organization; 2022."},{"key":"key-10.3201\/eid3103.241473-202502181628-R2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1164\/rccm.202311-2004OC","article-title":"High-dose isoniazid lacks EARLY bactericidal activity against isoniazid-resistant tuberculosis mediated by katG mutations: a randomized, phase 2 clinical trial.","volume":"210","author":"Gausi","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid3103.241473-202502181628-R3","doi-asserted-by":"publisher","first-page":"1701340","DOI":"10.1183\/13993003.01340-2017","article-title":"High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.","volume":"50","author":"Chesov","year":"2017","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid3103.241473-202502181628-R4","unstructured":"World Health Organization. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Geneva: The Organization; 2021."},{"key":"key-10.3201\/eid3103.241473-202502181628-R5","unstructured":"World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, 2nd ed. Geneva: The Organization; 2023."},{"key":"key-10.3201\/eid3103.241473-202502181628-R6","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1164\/rccm.201910-1960OC","article-title":"Early bactericidal activity of different isoniazid doses for drug-resistant TB (INHindsight): a randomized open-label clinical trial.","volume":"201","author":"Dooley","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid3103.241473-202502181628-R7","doi-asserted-by":"publisher","first-page":"100387","DOI":"10.1016\/j.jctube.2023.100387","article-title":"Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance.","volume":"33","author":"Lale Ngema","year":"2023","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"key-10.3201\/eid3103.241473-202502181628-R8","doi-asserted-by":"publisher","first-page":"e00092","DOI":"10.1128\/AAC.00092-19","article-title":"Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype composed of overlapping MIC distributions with different underlying resistance mechanisms.","volume":"63","author":"Ghodousi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid3103.241473-202502181628-R9","first-page":"139","article-title":"A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.","volume":"12","author":"Katiyar","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid3103.241473-202502181628-R10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.5588\/ijtld.18.0324","article-title":"NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis.","volume":"23","author":"Richardson","year":"2019","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:56:58Z","timestamp":1740178618000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/31\/3\/24-1473_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3103.241473","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}